Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roivant Sciences Ltd.

19.87
+0.27001.38%
Pre-market: 19.78-0.0900-0.45%08:34 EST
Volume:11.64M
Turnover:229.24M
Market Cap:13.57B
PE:-28.71
High:19.89
Open:19.33
Low:19.32
Close:19.60
52wk High:20.09
52wk Low:8.73
Shares:683.00M
Float Shares:414.56M
Volume Ratio:1.32
T/O Rate:2.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6921
EPS(LYR):-0.2371
ROE:-18.15%
ROA:-12.59%
PB:3.12
PE(LYR):-83.81

Loading ...

Roivant Sciences Ltd reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 11

Roivant Sciences Q1 Revenue USD 2.17 Million

Reuters
·
Aug 11

Roivant Sciences Q1 2026 Adj. EPS $(0.25) Beats $(0.30) Estimate, Sales $2.170M Down From $7.990M YoY

Benzinga
·
Aug 11

Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q1 Net Loss $0.33 a Share, vs. FactSet Est of $0.28 Loss

MT Newswires Live
·
Aug 11

Roivant Sciences Ltd. Reports Q1 Loss of $223.4M, EPS Declines to $(0.33)

Reuters
·
Aug 11

Roivant Sciences Q1 EPS USD -0.33

THOMSON REUTERS
·
Aug 11

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

THOMSON REUTERS
·
Aug 11

Roivant Sciences Ltd. Files Initial Statement of Beneficial Ownership for Frank Torti, President and Vant Chair

Reuters
·
Jul 30

Roivant Sciences Ltd. Announces Date for Annual General Meeting of Shareholders

Reuters
·
Jul 30

Roivant Sciences Ltd. to Announce Financial Results for First Quarter of 2025

Reuters
·
Jul 29

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

THOMSON REUTERS
·
Jul 29

Eric Venker, President & Immunovant CEO, Reports Disposal of Common Shares in Roivant Sciences Ltd

Reuters
·
Jul 24

FACTBOX-US corporate heads who got involved in politics

Reuters
·
Jul 08

BRIEF-Roivant Sciences Authorizes $500 Million Share Repurchase Program

Reuters
·
Jun 25

Eric Venker, President & COO, Reports Disposal of Roivant Sciences Ltd. Common Shares

Reuters
·
Jun 25

Vivek Ramaswamy, 10% Owner, Reports Disposal of Common Shares in Roivant Sciences Ltd

Reuters
·
Jun 23

Law Firm Launches Investigation into Immunovant Inc. Over Alleged Fiduciary Breaches in Private Placement Deal

Reuters
·
Jun 21

Roivant Sciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 18

Vivek Ramaswamy, 10% Owner, Reports Disposal of Common Shares in Roivant Sciences Ltd

Reuters
·
Jun 07

Roivant Sciences Ltd. President & COO Eric Venker Reports Disposal of Common Shares

Reuters
·
Jun 05